BR112015021266A2 - modificações e novas composições de proteínas secretoglobinas humanas - Google Patents
modificações e novas composições de proteínas secretoglobinas humanasInfo
- Publication number
- BR112015021266A2 BR112015021266A2 BR112015021266A BR112015021266A BR112015021266A2 BR 112015021266 A2 BR112015021266 A2 BR 112015021266A2 BR 112015021266 A BR112015021266 A BR 112015021266A BR 112015021266 A BR112015021266 A BR 112015021266A BR 112015021266 A2 BR112015021266 A2 BR 112015021266A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- isoforms
- new compositions
- novel
- preparations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000011274 Secretoglobin Human genes 0.000 title abstract 2
- 108050001520 Secretoglobin Proteins 0.000 title abstract 2
- 230000004048 modification Effects 0.000 title abstract 2
- 238000012986 modification Methods 0.000 title abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 4
- 108010029485 Protein Isoforms Proteins 0.000 abstract 4
- 238000002360 preparation method Methods 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 101000777301 Homo sapiens Uteroglobin Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000055576 human SCGB1A1 Human genes 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000007845 reactive nitrogen species Substances 0.000 abstract 1
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/843,773 US9394349B2 (en) | 2013-03-15 | 2013-03-15 | Modification and compositions of human secretoglobin proteins |
| PCT/US2014/030117 WO2014145368A2 (en) | 2013-03-15 | 2014-03-17 | Modification and novel compositions of human secretoglobin proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015021266A2 true BR112015021266A2 (pt) | 2017-10-10 |
Family
ID=51530119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015021266A BR112015021266A2 (pt) | 2013-03-15 | 2014-03-17 | modificações e novas composições de proteínas secretoglobinas humanas |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9394349B2 (enExample) |
| EP (2) | EP3403666A1 (enExample) |
| JP (2) | JP6670987B2 (enExample) |
| KR (1) | KR20160030076A (enExample) |
| CN (1) | CN105744946A (enExample) |
| AU (1) | AU2014233127A1 (enExample) |
| BR (1) | BR112015021266A2 (enExample) |
| CA (1) | CA2907439A1 (enExample) |
| IL (1) | IL241417A0 (enExample) |
| MX (1) | MX2015013092A (enExample) |
| RU (1) | RU2015144360A (enExample) |
| SG (1) | SG11201507277YA (enExample) |
| WO (1) | WO2014145368A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9394349B2 (en) * | 2013-03-15 | 2016-07-19 | Therabron Therapeutics, Inc. | Modification and compositions of human secretoglobin proteins |
| US12162914B2 (en) | 2013-03-15 | 2024-12-10 | Apc Research Assets Llc | Modification and compositions of human secretoglobin proteins |
| CA2971864A1 (en) * | 2014-12-22 | 2016-06-30 | The Regents Of The University Of California | Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| JP2022509856A (ja) * | 2018-11-30 | 2022-01-24 | エーピーシー リサーチ アセッツ，エルエルシー | ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1006919A3 (nl) * | 1993-03-15 | 1995-01-24 | Ley Marc Jozef Philemon De | Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum. |
| US20040047857A1 (en) * | 1997-05-28 | 2004-03-11 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| US20060281681A1 (en) * | 1997-05-28 | 2006-12-14 | Pilon Aprile L | Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease |
| US20030008816A1 (en) | 1997-05-28 | 2003-01-09 | Pilon Aprile L. | Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production |
| AU5551299A (en) | 1998-08-13 | 2000-03-06 | Trustees Of The University Of Pennsylvania, The | Method of identifying proteins |
| US6953666B1 (en) | 1998-11-06 | 2005-10-11 | Emory University | Biomarkers for oxidative stress |
| WO2004101824A1 (ja) | 2003-05-14 | 2004-11-25 | Shionogi & Co., Ltd. | 慢性閉塞性肺疾患の検出方法 |
| EP1654379A4 (en) | 2003-06-26 | 2007-01-17 | Lifesensors Inc | METHOD AND COMPOSITIONS FOR IMPROVED PROTEIN EXPRESSION AND CLEANING |
| CN1580261A (zh) * | 2003-08-06 | 2005-02-16 | 上海富纯中南生物技术有限公司 | Cc10蛋白的制备及应用 |
| JP2007511517A (ja) | 2003-11-14 | 2007-05-10 | アルザ・コーポレーシヨン | 薬剤と照射を受けた賦形剤の製剤の中の薬剤の酸化を最小化 |
| US20060275794A1 (en) | 2005-03-07 | 2006-12-07 | Invitrogen Corporation | Collections of matched biological reagents and methods for identifying matched reagents |
| US8133859B2 (en) | 2006-09-27 | 2012-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | SCGB3A2 as a growth factor and anti-apoptotic agent |
| US20090004684A1 (en) | 2007-05-23 | 2009-01-01 | Claudia Susanne Maier | Compositions and Methods for Detection and Quantification of Protein Oxidation |
| CA2813740C (en) * | 2009-10-15 | 2016-08-02 | Clarassance, Inc. | Recombinant human cc10 protein for treatment of influenza |
| US9394349B2 (en) * | 2013-03-15 | 2016-07-19 | Therabron Therapeutics, Inc. | Modification and compositions of human secretoglobin proteins |
-
2013
- 2013-03-15 US US13/843,773 patent/US9394349B2/en active Active
-
2014
- 2014-03-17 MX MX2015013092A patent/MX2015013092A/es unknown
- 2014-03-17 BR BR112015021266A patent/BR112015021266A2/pt not_active IP Right Cessation
- 2014-03-17 AU AU2014233127A patent/AU2014233127A1/en not_active Abandoned
- 2014-03-17 CN CN201480015618.3A patent/CN105744946A/zh active Pending
- 2014-03-17 JP JP2016503333A patent/JP6670987B2/ja active Active
- 2014-03-17 RU RU2015144360A patent/RU2015144360A/ru unknown
- 2014-03-17 EP EP18167516.6A patent/EP3403666A1/en active Pending
- 2014-03-17 EP EP14765106.1A patent/EP2968449A4/en not_active Withdrawn
- 2014-03-17 KR KR1020157029582A patent/KR20160030076A/ko not_active Ceased
- 2014-03-17 WO PCT/US2014/030117 patent/WO2014145368A2/en not_active Ceased
- 2014-03-17 SG SG11201507277YA patent/SG11201507277YA/en unknown
- 2014-03-17 CA CA2907439A patent/CA2907439A1/en not_active Abandoned
-
2015
- 2015-09-09 IL IL241417A patent/IL241417A0/en unknown
-
2016
- 2016-07-17 US US15/212,277 patent/US10294285B2/en active Active
-
2019
- 2019-05-20 US US16/416,268 patent/US10676513B2/en active Active
- 2019-12-02 JP JP2019218277A patent/JP2020055833A/ja active Pending
-
2020
- 2020-06-09 US US16/896,213 patent/US20200325190A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015144360A (ru) | 2017-04-24 |
| EP3403666A1 (en) | 2018-11-21 |
| US10676513B2 (en) | 2020-06-09 |
| JP2016515532A (ja) | 2016-05-30 |
| CN105744946A (zh) | 2016-07-06 |
| US9394349B2 (en) | 2016-07-19 |
| AU2014233127A1 (en) | 2015-09-24 |
| US20200325190A1 (en) | 2020-10-15 |
| EP2968449A4 (en) | 2017-03-22 |
| US20190337999A1 (en) | 2019-11-07 |
| JP6670987B2 (ja) | 2020-03-25 |
| EP2968449A2 (en) | 2016-01-20 |
| MX2015013092A (es) | 2016-06-02 |
| IL241417A0 (en) | 2015-11-30 |
| JP2020055833A (ja) | 2020-04-09 |
| WO2014145368A2 (en) | 2014-09-18 |
| CA2907439A1 (en) | 2014-09-18 |
| WO2014145368A3 (en) | 2014-11-27 |
| KR20160030076A (ko) | 2016-03-16 |
| US20160362462A1 (en) | 2016-12-15 |
| US10294285B2 (en) | 2019-05-21 |
| US20140275477A1 (en) | 2014-09-18 |
| SG11201507277YA (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112015021266A2 (pt) | modificações e novas composições de proteínas secretoglobinas humanas | |
| BR112021010354A2 (pt) | Métodos para o tratamento usando terapia celular adotiva | |
| BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
| BR112017016336A2 (pt) | proteínas de ligação icos agonistas? | |
| BR112014019459A8 (pt) | Proteínas de ligação à cdim e usos das mesmas | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| BR112015024926A2 (pt) | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe | |
| CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
| ATE500319T1 (de) | Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz- kreislauf-leiden | |
| IN2014CN04645A (enExample) | ||
| CY1118073T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης | |
| BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
| MX2015016120A (es) | Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos. | |
| Ahmadifaraz et al. | The experiences of employed women related to their maternal role: A phenomenological qualitative research | |
| BR112016014072A8 (pt) | anticorpo isolado, sintético ou recombinante humano, ou uma parte funcional ou um equivalente funcional do mesmo, molécula de ácido nucleico isolado, sintético ou recombinante, vetor, célula isolada ou recombinante ou um animal não humano, composição, uso de um anticorpo ou parte funcional ou equivalente funcional, e, métodos para produzir um anticorpo ou parte funcional ou equivalente funcional, para detectar células mieloproliferativas ou linfoproliferativas, para determinar se uma célula mieloide ou célula linfoide é uma célula mieloproliferativa ou célula linfoproliferativa, para identificar células mieloproliferativas ou linfoproliferativas, para determinar se células mieloproliferativas ou linfoproliferativas estão presentes em uma amostra, para tratar e/ou prevenir um distúrbio mieloproliferativo ou linfoproliferativo, para determinar se um indivíduo sofre de um distúrbio mieloproliferativo ou linfoproliferativo, para tipificar uma amostra contendo célula mieloide ou uma amostra contendo célula linfoide de um indivíduo, e, para determinar se um paciente que sofre de um distúrbio mieloproliferativo ou distúrbio linfoproliferativo é um candidato para o tratamento com um anticorpo | |
| BR112012010994A2 (pt) | revestimentos e métodos de revestimento de agulhas cirúrgicas | |
| MX387579B (es) | Polipéptidos del factor vii de acción corta. | |
| BR112015019568A2 (pt) | Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo | |
| BR112013009660A2 (pt) | proteína de fusão com fator de atividade ix | |
| BR112012030821A2 (pt) | vitronectina:fator de crescimento quimeras queratinócitos | |
| BR112018000655A2 (pt) | peptídeos promotores do crescimento e seu uso | |
| BR112014023496A2 (pt) | mutantes c-raf que conferem resistência a inibidores de raf | |
| BR112021017863A2 (pt) | Proteína de ligação de antígeno de membrana específico de próstata, composição, método para produzir a proteína de ligação de antígeno de membrana específico de próstata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: CLARASSANCE, INC. (US) Free format text: A FIM DE ATENDER AS ALTERACOES DE NOME E SEDE REQUERIDAS ATRAVES DA PETICAO NO 870160012526, DE 05/04/2016, E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO DEVIDAMENTE NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR, UMA GUIA DE RECOLHIMENTO, CODIGO 248, RELATIVA AO SEGUNDO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. Owner name: CLARASSANCE, INC. (US) |
|
| B25E | Requested change of name of applicant rejected |
Owner name: CLARASSANCE, INC. (US) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2558 DE 14/01/2020. |